Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis
Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995) · Science · doi:10.1126/science.270.5240.1326 · Cited by 5,287
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×
“The cell cycle checkpoint genes p53 and p21CIP1, both of which are involved in cell cycle arrest following DNA damage (Bunz et al., 1998), have also been shown to modulate cellular di erentiation and apoptotic responses in a reciprocal manner.”
BackgroundSocial controls on cell survival and cell death
Raff, M. C. (1992) · Nature · doi:10.1038/356397a0 · Cited by 2,604
Establishment and characterization of a human histiocytic lymphoma cell line (U‐937)
Sundström, C., & Nilsson, K. (1976) · International Journal of Cancer · doi:10.1002/ijc.2910170504 · Cited by 2,407
Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture
COLLINS, S. J., GALLO, R. C., & GALLAGHER, R. E. (1977) · Nature · doi:10.1038/270347a0 · Cited by 2,094
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
Verheij, M., Bose, R., Hua Lin, X., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szabo, E., Zon, L. I., Kyriakis, J. M., et al. (1996) · Nature · doi:10.1038/380075a0 · Cited by 1,767
Self-citationA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citationMichalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769
The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest
Dunaief, J. L., Strober, B. E., Guha, S., Khavari, P. A., Ålin, K., Luban, J., Begemann, M., Crabtree, G. R., & Goff, S. P. (1994) · Cell · doi:10.1016/0092-8674(94)90405-7 · Cited by 624
p21 WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells
Archer, S. Y., Meng, S., Shei, A., & Hodin, R. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6791 · Cited by 535
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Self-citationHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
“here, divergent views exist regarding the importance of the intrinsic apoptotic pathway mediated by the interplay between proapoptotic and antiapoptotic Bcl-2 family proteins (41, 42, 44), versus the extrinsic pathway mediated by death receptors (e.”
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
“They regulate transcription of pro-apoptotic genes such as Bid (BH3 interacting domain death agonist protein), Bad (Bcl-2 associated agonist of cell death protein) and Bim that activate the intrinsic apoptotic pathway [42,58,63,64].”
BackgroundInfluentialRichon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationGui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Self-citationPeart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Self-citation(2003) · PubMed · Cited by 519
Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Donà, G., Fossati, G., Sozzani, S., Azam, T., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052702999 · Cited by 508
Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191208598 · Cited by 488
(2003) · PubMed · Cited by 465
Histone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
Pei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382
Self-citationGRØNBÆK, K., HOTHER, C., & JONES, P. A. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_636.xml.x · Cited by 366
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Duvic, M., & Vu, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1111 · Cited by 344
Huang, B. H., Laban, M., Leung, C. H.-W., Lee, L., Lee, C. K., Salto-Tellez, M., Raju, G. C., & Hooi, S. C. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401567 · Cited by 337
Musa, J., Aynaud, M.-M., Mirabeau, O., Delattre, O., & Grünewald, T. G. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.244 · Cited by 322
Epigenetics—An Epicenter of Gene Regulation: Histones and Histone‐Modifying Enzymes
Biel, M., Wascholowski, V., & Giannis, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461346 · Cited by 316
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
He, L.-Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R. P., Rifkind, R. A., Marks, P. A., Richon, V. M., & Pandolfi, P. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11537 · Cited by 303
Self-citationMolecular sequelae of histone deacetylase inhibition in human malignant B cells
Mitsiades, N., Mitsiades, C. S., Richardson, P. G., McMullan, C., Poulaki, V., Fanourakis, G., Schlossman, R., Chauhan, D., Munshi, N. C., Hideshima, T., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3514 · Cited by 294
Self-citationDifferentiation therapy of human cancer: basic science and clinical applications
Leszczyniecka, M., Roberts, T., Dent, P., Grant, S., & Fisher, P. B. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00132-2 · Cited by 292
Self-citationHistone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
Self-citationYu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P., & Grant, S. (2003) · Blood · doi:10.1182/blood-2003-03-0737 · Cited by 259
Self-citationHistone deacetylase as a therapeutic target
Krämer, O. H., Göttlicher, M., & Heinzel, T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00438-6 · Cited by 257
Histone deacetylase inhibitors: from target to clinical trials
Kelly, W. K., O’Connor, O. A., & Marks, P. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1695 · Cited by 253
Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
Almenara, J., Rosato, R., & Grant, S. (2002) · Leukemia · doi:10.1038/sj.leu.2402535 · Cited by 141
Self-citationHistone deacetylase inhibitors: Anticancer compounds
Smith, K. T., & Workman, J. L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.008 · Cited by 90
New molecular targeted therapies in thyroid cancer
Milano, A., Chiofalo, M. G., Basile, M., Salzano de Luna, A., Pezzullo, L., & Caponigro, F. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000224449.16329.c5 · Cited by 26
Metadata
- Authors
- Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S.
- Venue
- Oncogene
- Published
- 1999-11-25
- Volume
- 18
- Issue
- 50
- Pages
- 7016-7025
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2034420402
- Cited by
- 284
- References
- 32
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.